Multimodality Treatment and Long-Term Follow–Up of the Primary Pulmonary Lymphoepithelioma-Like Carcinoma

Huang, Chung-Jen; Feng, An‐Chen; Fang, Yueh‐Fu; Ku, Wen-Hui; Chu, Nai‐Shin; Yu, Chih-Teng; Liu, Chia‐Chuan; Lee, Ming-Yuan; Hsu, Li‐Han; Tsai, Shih Chang; Shih, Chun‐Hsing; Wang, Chih‐Liang

doi:10.1016/j.cllc.2012.01.002

Cited by 47 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with pulmonary LELC exhibited a favorable prognosis compared with that of patients with other types of NSCLC; furthermore, patients with the former achieved increased survival time and improved overall survival (OS) rates under multimodality treatment (23,25). According to a previous study (12), the 2-and 5-year OS rates were 81 and 51%, respectively, in patients who received complete resection or chemotherapy or radiotherapy.…”

Section: Discussionmentioning

confidence: 88%

“…The majority of case studies have suggested that pulmonary LELC is sensitive to chemotherapy. A previous study demonstrated that surgery and adjuvant chemotherapy provided an improved prognosis for patients in early-stage LELC and advanced-stage LELC exhibited an increased sensitivity to chemotherapy and radiotherapy (25). For advanced pulmonary LELC, platinum-based chemotherapy is regarded as the first-line treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Lin

Zeng

2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Advanced lung cancer is considered to exhibit a poor prognosis; however, the pulmonary lymphoepithelioma-like carcinoma (LELC), a rare subtype of non-small cell lung cancer (NSCLC), exhibits an improved prognosis, compared with non-LELC. The present study aimed at investigating the clinical manifestation, imaging characteristics, pathology, tumor markers, treatment and prognosis of primary LELC of the lung. A total of 14 patients with pulmonary LELC were confirmed by surgery and pathology. Clinical data of those patients were retrospectively reviewed including age, sex, smoking history, symptoms, computed tomography (CT) results, Epstein-Barr virus-encoded RNA (EBER) status, treatment and outcomes. In the present study, there were 7 males and 7 females who ranged in age between 22 and 64 years (mean, 51.21±11.37 years) and who all were from eastern China. The tumor-node-metastasis stage ranged between stages I and IV, with 71.43% of the patients at advanced stage (stages III and IV). The results of the present study identified 100% positive expression of EBER. Tumors located centrally were of significantly increased size, compared with peripheral tumors (P<0.05), and lymphadenopathy was more common in patients with advanced stage (P<0.05). The majority of patients were treated with surgery, platinum-based chemotherapy or radiotherapy. At time of writing, 12 patients were alive and the longest survival time was 60 months. Pulmonary LELC typically affected young patients and was not associated with smoking history; however, pulmonary LELC was associated with Epstein-Barr virus infection in the Asian population. The majority of patients were in early or locally advanced stages and exhibit an improved prognosis compared with other types of NSCLC. Pulmonary LELC was sensitive to chemotherapy and surgery, with postoperative chemotherapy-based multimodality treatment recommended.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Lin

Zeng

2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The platinum/based chemotherapy can be used as the first-line of treatment for LELC at an advanced stage (24). The responsivity of LELC for 5-FU/folic acid/ cisplatin treatment was 60% (25); capecitabine alone could be used as the salvage chemotherapy to maintain the stability of disease (26).…”

Section: Resultsmentioning

confidence: 99%

“…In general, the OS of LELC was better than that of other subtypes of non-small cell lung cancer (NSCLC) (4,24). The prognosis of the three LCC subtypes was compared by Sun et al, including 46 typical LCC, 30 large cell neuroendocrine carcinomas (LCNEC), and 18 LELC.…”

Section: Resultsmentioning

confidence: 99%

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

et al. 2016

View full text Add to dashboard Cite

Background: Lymphoepithelioma-like carcinoma (LELC) is a rare form of non-small cell lung carcinoma.The current study focused on its clinicopathological features and potential factors influencing the prognosis.Methods: The statistical analysis was based on the clinicopathological records and the prognosis of 43 LELC patients, analyzed by Kaplan-Meier method, Log-rank test, and COX regression analysis.Results: The patients' average age was 57.35±9.22 years, 86.05% of them were non-smokers and 53.49%were women. The average tumor diameter was 3.24±1.57 cm. The 2-and 5-year overall survival (OS) rates of LELC patients were 90% and 74%, respectively; the disease-free survival (DFS) rates were 87% and 47%, respectively. The patients with large tumor, accompanied with lymph nodes metastasis or at the advanced stage had the worst OS, and the patients with lymph nodes metastasis or at the advanced stage had the worst DFS. Univariate analysis indicated that T and N grading and TNM stage influenced the OS, and N grading and TNM stage influenced the DFS; the independent factors affecting OS or DFS were not identified by multivariate analysis. Conclusions: LELC commonly occurred in senior non-smoking women. In summary, the prognosis of LELC was satisfactory.

show abstract

“…New studies are needed for new treatment modalities. [13][14][15][16] Six courses of platinum-based chemotherapy were administered following surgery in our patient. At the present time, she is in remission and being followed up.…”

Section: Discussionmentioning

confidence: 99%

Primary Lymphoepithelioma-Like Carcinoma of the Lung

Tanrıverdi¹

2017

TJ Oncol

View full text Add to dashboard Cite

SUMMARYPrimary lymphoepithelioma-like carcinoma (LELC) is a rare tumor of the lung. LELC may also be seen in the nasopharynx, salivary glands, stomach, or thymus. These tumors are often associated with Epstein-Barr virus infection. Patient presenting with left hilar fullness and peripheral nodule in the left lung was admitted to our clinic for diagnostic examination. Postoperative histopathological results of sample confirmed diagnosis of LELC of the lung. LELC is classified as subtype of non-small cell lung cancer; however, prognosis is better than non-LELC type of non-small cell lung carcinoma. Presently described is a case of this rare disease.

show abstract

Multimodality Treatment and Long-Term Follow–Up of the Primary Pulmonary Lymphoepithelioma-Like Carcinoma

Cited by 47 publications

References 20 publications

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

Primary Lymphoepithelioma-Like Carcinoma of the Lung

Contact Info

Product

Resources

About